Author

Guang Hu

Institution: Nanjing IASO Biotechnology Co., Ltd. (China)

Observed institutions: Xiyuan Hospital, China Academy of Chinese Medical Sciences, Nanjing IASO Biotechnology Co., Ltd. (China), Xi'an Jiaotong University

ORCID: 0000-0002-3639-6110

Observed ORCID: 0000-0002-3639-6110

OpenAlex ID: A5080652098

Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy

2025 · Jiahao Liu, Xiaofei Jiao, et al. · Science Translational Medicine · 19

Platelets lipidomics study of blood stasis rat model by using liquid chromatography‐tandem mass spectrometry

2022 · Mingqian Sun, Ying Li, et al. · Journal of Separation Science · 7

Metabolic Biomarkers Affecting Cell Proliferation and Prognosis in Polycythemia Vera

2022 · Ziqing Wang, Yan Lv, et al. · Cancers · 7

Investigation of Groove Damage Distribution in Proton‐Induced Clustered B‐ DNA Damage

2025 · Shanshan Bao, Guang Hu, et al. · Environmental and Molecular Mutagenesis · 1

Elucidating Structural Epitope Mapping and Soluble BCMA in the Microenvironment: Impact on Anti-BCMA CAR-T Cell Functionality

2024 · Wei Mu, Ning An, et al. · Blood · 1

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy (Adv. Sci. 53/2026)

2026 · Huayi Li, Minghua Xiang, et al. · Advanced Science

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

2026 · Huayi Li, Minghua Xiang, et al. · Advanced Science

Works count: 7

Citation count: 35

H-index: 3

I10-index: 1